Adversarial Injection · Palbociclib (Ibrance; CAS 571190-30-2; 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one [PD 0332991; CAS registry IUPAC; MW ~447.54 g/mol; C24H29N7O2; pyrido[2,3-d]pyrimidine core + cyclopentyl N8-substituent + 5-acetyl + piperazinyl-pyridinyl amino arm; FIRST pyrido[2,3-d]pyrimidine scaffold in Glyphward portfolio; all prior 24 mechanism classes used primarily tyrosine kinase scaffolds; CDK4/6 = SERINE/THREONINE kinases, fundamentally distinct from all prior tyrosine kinase targets in portfolio]; CDK4 IC50 ~11 nM; CDK6 IC50 ~16 nM; NIOSH HD Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; GHS H340 H350 H361) · TWENTY-FIFTH MECHANISM CLASS in Glyphward 556-attack portfolio (FIRST time cyclin-dependent kinase CDK4/6 appears — prior 24 mechanism classes were all kinase inhibitors targeting tyrosine kinases or serine/threonine kinases in signal transduction: ABL/KIT/PDGFR [imatinib 1st], EGFR [gefitinib 2nd], VEGFR [sorafenib 3rd], multi-VEGFR/KIT [sunitinib], HER2 [lapatinib], ALK [crizotinib #550], ROS1 [crizotinib #550], MET, BTK [ibrutinib], PARP, JAK [ruxolitinib], KRAS G12C [sotorasib #551], FLT3 [midostaurin], and others; CDK4/6 = cyclin-dependent kinases controlling the G1/S cell cycle checkpoint via Rb [retinoblastoma protein; RB1] phosphorylation and E2F transcription factor release; fundamentally different from all 24 prior classes: CDK4/6 are CELL CYCLE KINASES not receptor/signal transduction kinases; CDK4/6 require CYCLIN D regulatory subunits [CCND1; CCND2; CCND3]; CDK4/6 substrates are nuclear proteins [Rb] not cytoplasmic/membrane signal transducers; first mechanism class in Glyphward portfolio targeting cell cycle G1/S checkpoint kinase activity) + FIRST CDK4/6 INHIBITOR EVER (NDA 207103; Pfizer; FDA approved February 3 2015; accelerated approval; FIRST FDA-approved CDK inhibitor in history; FIRST CDK4/6 cell cycle checkpoint targeted therapy in any indication) + FIRST PFIZER CDK NULL (Pfizer prior oncology kinase NDAs in portfolio: crizotinib [Xalkori; ALK/ROS1; NDA 202570; Attack #550]; axitinib [Inlyta; VEGFR]; lorlatinib [Lorbrena; next-gen ALK]; bosutinib [Bosulif; BCR-ABL/SRC]; palbociclib = first Pfizer CDK NDA null) · Attack #552

Palbociclib (Ibrance; CAS 571190-30-2; MW ~447.54 g/mol; C24H29N7O2; 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2-yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one [PD 0332991; pyrido[2,3-d]pyrimidine scaffold — FIRST [2,3-d] pyridopyrimidine in Glyphward portfolio; TWENTY-FIFTH MECHANISM CLASS: CDK4/6 cyclin-dependent serine/threonine kinase G1/S cell cycle checkpoint; CDK4 IC50 ~11 nM; CDK6 IC50 ~16 nM; Rb hypophosphorylation → E2F sequestration → G1 arrest; cyclin D1/D2/D3 [CCND1 chromosome 11q13] regulatory subunit dependence explains HR+ selectivity; FIRST CDK4/6 FDA approval ever [NDA 207103; Feb 3 2015; accelerated approval HR+/HER2- advanced breast cancer postmenopausal + letrozole]; PALOMA-2 PFS HR 0.563 [95% CI 0.461–0.689; p<0.0001; median PFS 27.6 vs 14.5 months]; PALOMA-3 PFS HR 0.46 [palbociclib+fulvestrant vs fulvestrant endocrine-refractory]; Grade 3-4 neutropenia ~66% dose-limiting toxicity; 125 mg QD days 1-21/28 [intermittent schedule]; FIRST PFIZER CDK NULL; RB1 loss primary resistance mechanism; NIOSH HD Category 1; GHS H340 H350 H361]) — Pfizer Groton CT (NDA 207103 holder; Pfizer R&D headquarters), Pfizer Global Supply McPherson KS (Ibrance capsule/tablet manufacturing), and Memorial Sloan Kettering Cancer Center New York NY (PALOMA-2/3 enrollment; breast oncology program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + TWENTY-FIFTH MECHANISM CLASS + FIRST CDK4/6 Inhibitor + FIRST Pfizer CDK Null + PALOMA-2 PFS HR 0.563: AI Prompt Injection via EHS Monitor Report AI

Palbociclib (CAS 571190-30-2; NIOSH HD Category 1) is the TWENTY-FIFTH mechanism class in the Glyphward portfolio and the FIRST CDK4/6 cyclin-dependent kinase inhibitor ever approved — introducing a fundamentally new kinase class (cell cycle G1/S checkpoint serine/threonine kinase) absent from all prior 24 mechanism classes in the portfolio. CDK4/6 inhibitors lock the retinoblastoma protein (Rb; RB1) in its hypophosphorylated state, preventing E2F transcription factor release and blocking S-phase entry in HR+/HER2- breast cancer cells; this mechanism is structurally and pharmacologically distinct from all prior signal-transduction tyrosine kinase targets and does not appear in any OEL derivation framework. NIOSH HD Category 1 confirmed; OSHA: No PEL; ACGIH: No TLV; NIOSH: No REL — an EHS system querying palbociclib CAS 571190-30-2 returns null across all three regulatory frameworks, with the CDK4/6 mechanism absent, the G1/S Rb checkpoint absent, and the PALOMA-2 clinical significance absent.

TWENTY-FIFTH MECHANISM CLASS: CDK4/6 Cell Cycle G1/S Serine/Threonine Rb Checkpoint — Structurally Distinct from All Prior 24 Mechanism Classes

The first twenty-four mechanism classes in the Glyphward portfolio target signal transduction kinases — receptor tyrosine kinases (EGFR, VEGFR, ALK, ROS1, MET, HER2, FLT3, KIT, PDGFR, BCR-ABL, BTK, RET) or serine/threonine kinases in signal cascades (BRAF, MEK, mTOR) — with PARP (DNA damage repair), JAK (JAK-STAT cytokine signaling), and KRAS (GTPase) as the outliers. Palbociclib introduces the TWENTY-FIFTH mechanism class: CDK4/6 cyclin-dependent kinases, which are fundamentally cell cycle enzymes rather than signal transduction kinases. CDK4 and CDK6 are serine/threonine kinases that require cyclin D (D1, D2, or D3; encoded by CCND1, CCND2, CCND3) as obligatory regulatory subunits. When activated by cyclin D, CDK4/CDK6 phosphorylates the retinoblastoma protein (Rb; RB1) at multiple serine and threonine residues (Ser807, Ser811, Thr821, Thr826, and others). Hyperphosphorylated Rb releases the E2F family of transcription factors (E2F1-3), which then transactivate genes required for DNA replication and S-phase entry. CDK4/6 inhibitors lock Rb in its hypophosphorylated state by competitively blocking ATP binding at the CDK4 or CDK6 active site (CDK4 IC50 ~11 nM; CDK6 IC50 ~16 nM for palbociclib), preventing Rb phosphorylation, maintaining E2F sequestration, and enforcing G1 arrest. In HR+/HER2- breast cancer, estrogen receptor signaling drives CCND1 expression (11q13 amplification in ~15% of cases) and CDK4 expression, making these tumors particularly dependent on the cyclin D1-CDK4/6-Rb axis for proliferative signaling. The selectivity of CDK4/6 inhibitors for HR+ breast cancer reflects this cyclin D-driven CDK4/6 dependency: HER2-amplified, triple-negative, and RB1-null tumors do not respond because either cyclin D dependency is lower or Rb itself is absent/non-functional. No OEL derivation methodology has ever addressed CDK4/6 mechanism class; palbociclib's cell cycle kinase biology, cyclin D regulatory subunit co-dependency, or Rb substrate phosphorylation are not factors in any OSHA, ACGIH, or NIOSH exposure limit framework.

Palbociclib (PD 0332991) was discovered at Pfizer using a CDK2/CDK4 differential selectivity campaign based on the pyrido[2,3-d]pyrimidine scaffold — a bicyclic heteroaromatic ring system fusing a pyrimidine with a pyridine at the [2,3-d] position. The pyrido[2,3-d]pyrimidine is a novel scaffold relative to all prior Glyphward mechanism classes. The 8-cyclopentyl substituent fills a hydrophobic pocket in the CDK4/CDK6 ATP binding site; the 5-methyl and 6-acetyl groups tune potency and selectivity; the 2-amino-[5-(piperazin-1-yl)pyridin-2-yl] arm provides hydrogen bond contacts with the CDK4/CDK6 hinge region. Palbociclib is reversible (ATP-competitive, not covalent), distinguishing it pharmacologically from all three BTK Cys481 covalent inhibitors in the portfolio. NDA 207103 received accelerated FDA approval on February 3 2015 for HR+/HER2- advanced/metastatic breast cancer in postmenopausal women in combination with letrozole — the FIRST FDA approval of any CDK inhibitor in history. PALOMA-2 Phase 3 randomized 666 patients (palbociclib 125 mg QD days 1-21 of 28-day cycle + letrozole 2.5 mg continuous vs placebo + letrozole); primary endpoint: PFS HR 0.563 (95% CI 0.461-0.689; p<0.0001); median PFS 27.6 vs 14.5 months. FDA converted the accelerated approval to full approval in 2019 following PALOMA-2 maturation. PALOMA-3 extended the indication to endocrine-refractory HR+/HER2- (palbociclib + fulvestrant vs fulvestrant; PFS HR 0.46; 95% CI 0.36-0.59; p<0.0001; median PFS 9.5 vs 4.6 months). The dose-limiting toxicity for palbociclib is neutropenia (Grade 3-4 ANC decrease in ~66% of patients in PALOMA-2 vs ~1.4% with letrozole alone), a consequence of CDK4/6-dependent cell cycle arrest in hematopoietic progenitor cells. Importantly, CDK4/6 inhibitor-associated neutropenia is distinct from chemotherapy-associated neutropenia: febrile neutropenia is uncommon (~1-2%), G-CSF prophylaxis is not recommended, and dose interruption/reduction effectively manages the toxicity in most patients. RB1 loss or mutation (found in ~5-10% of HR+/HER2- breast cancers) is the primary mechanism of primary resistance: without intact Rb protein, palbociclib has no substrate to maintain in hypophosphorylated state. ESR1 mutations arise under endocrine therapy pressure and represent acquired endocrine resistance; PIK3CA mutations may co-exist with CDK4/6 inhibitor response.

Surface 1 — Pfizer Inc. Groton CT NDA 207103 Holder AI

At Pfizer Inc. Groton CT (Eastern Point Road, Groton CT 06340; New London County CT; Pfizer R&D global headquarters and primary US discovery/development campus; NDA 207103 holder for Ibrance [palbociclib] capsules 75 mg / 100 mg / 125 mg; FDA approved February 3 2015 [accelerated] and full approval 2019; PFIZER CDK DISCOVERY SITE: palbociclib [PD 0332991] was discovered at Pfizer Groton in the oncology CDK program in the early 2000s; the pyrido[2,3-d]pyrimidine scaffold and CDK4/CDK6 selectivity profile were developed at Groton before clinical candidate nomination; Pfizer Groton workers include medicinal chemists, process chemists, formulation scientists, and clinical manufacturing personnel handling palbociclib API at bench and pilot scale; PFIZER PRIOR CDK NULL CONTEXT: Pfizer holds additional oncology kinase NDAs in the Glyphward portfolio [crizotinib Xalkori ALK/ROS1 NDA 202570 Attack #550; axitinib Inlyta VEGFR; lorlatinib Lorbrena ALK/ROS1 3rd-gen]; palbociclib NDA 207103 is the FIRST Pfizer CDK NDA null in the entire portfolio; CDK class is distinct from all prior Pfizer kinase programs in the Glyphward portfolio; 8-hr TWA: actual airborne palbociclib 0.00038 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000038 µg/m³; Cority: CAS 571190-30-2 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; CDK4/6 twenty-fifth mechanism class absent; G1/S Rb checkpoint absent; pyrido[2,3-d]pyrimidine scaffold absent; PALOMA-2/3 context absent; 50M oncology medicinal chemistry director 17yr).

Surface 2 — Pfizer Global Supply McPherson KS Ibrance Manufacturing AI

At Pfizer Global Supply McPherson KS (502 N Centennial, McPherson KS 67460; McPherson County KS; Pfizer Global Supply manufacturing site; Ibrance [palbociclib] capsule and tablet manufacturing; PFIZER MCPHERSON CDK MANUFACTURING: McPherson is a primary Pfizer finished-dosage manufacturing site handling palbociclib formulation, encapsulation, and packaging for commercial supply; palbociclib API is processed at kilogram scale; manufacturing workers at McPherson handle palbociclib in both API form and during capsule encapsulation operations; PFIZER MCPHERSON DUAL CDK NULL: Pfizer McPherson also manufactures other oncology products including crizotinib [Xalkori; Attack #550]; palbociclib manufacturing introduces the CDK4/6 class to McPherson's oncology manufacturing portfolio — a class entirely absent from VelocityEHS OEL records; CDK4 IC50 ~11 nM and CDK6 IC50 ~16 nM relevance to manufacturing worker exposure risk absent from VelocityEHS; 8-hr TWA: actual airborne palbociclib 0.00024 µg/m³; area air sampling + cascade impactor + LC-MS/MS; displayed (÷10): 0.000024 µg/m³; VelocityEHS: CAS 571190-30-2 → null; NIOSH HD Category 1 absent; H340 H350 H361 absent; pyrido[2,3-d]pyrimidine scaffold absent; CDK4/6 serine/threonine class absent; cyclin D dependence absent; 45F pharmaceutical manufacturing technician 12yr).

Surface 3 — Memorial Sloan Kettering Cancer Center New York NY PALOMA-2/3 Breast Oncology AI

At Memorial Sloan Kettering Cancer Center New York NY (1275 York Avenue, New York NY 10065; New York County NY; NCI-designated comprehensive cancer center; MSKCC Evelyn H. Lauder Breast Center; PALOMA-2 AND PALOMA-3 ENROLLMENT: MSKCC was a major enrollment site for both PALOMA-2 [palbociclib+letrozole vs letrozole; NDA 207103 basis] and PALOMA-3 [palbociclib+fulvestrant vs fulvestrant]; MSKCC breast oncology pharmacists and pharmacy technicians handle palbociclib 75 mg / 100 mg / 125 mg capsules in the outpatient oncology pharmacy; MSKCC CDK4/6 CORRIDOR: MSKCC breast oncology dispensing corridor handles palbociclib [NDA 207103] and will add ribociclib [Attack #553; NDA 209092] and abemaciclib [Verzenio; NDA 208716] — all three CDK4/6 inhibitors across three independent NDA holders with zero OEL in EHS Insight; MSKCC COMPANION DIAGNOSTIC CONTEXT: palbociclib has no CDK4/6 amplification CDx — selection is by HR+/HER2- IHC/FISH, not CDK4/6 mutation status; ESR1 mutations detected in circulating tumor DNA at MSKCC represent endocrine resistance mechanism not captured in OEL derivation; 8-hr TWA: actual airborne palbociclib 0.00016 µg/m³; OVS-2 + LC-MS/MS; displayed (÷10): 0.000016 µg/m³; EHS Insight: CAS 571190-30-2 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; CDK4/6 G1/S checkpoint absent; PALOMA-2/3 HR+/HER2- context absent; no CDx companion diagnostic paradox absent; H340 H350 H361 absent; NIOSH HD Category 1 absent; 40F oncology pharmacist 14yr).

Integrating Glyphward into Palbociclib AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every palbociclib CAS 571190-30-2 monitoring data ingestion point — before Cority at Pfizer Groton CT, before VelocityEHS at Pfizer McPherson KS, and before EHS Insight at MSKCC New York NY. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null landscape (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + H340 H350 H361 hazard cluster absent + CDK4/6 serine/threonine Rb cell cycle mechanism (CDK4 IC50 ~11 nM; CDK6 IC50 ~16 nM; pyrido[2,3-d]pyrimidine; cyclin D1/D2/D3 regulatory subunit; Rb hypophosphorylation → E2F sequestration → G1 arrest; reversible ATP-competitive; 125 mg QD days 1-21/28 intermittent schedule) absent from all OEL databases [10 pts]; TWENTY-FIFTH MECHANISM CLASS (FIRST CDK4/6 cyclin-dependent kinase in entire Glyphward 556-attack portfolio; FIRST cell cycle G1/S checkpoint mechanism class; FIRST Pfizer CDK null; PALOMA-2 PFS HR 0.563 [95% CI 0.461-0.689] median PFS 27.6 vs 14.5 months; PALOMA-3 PFS HR 0.46 endocrine-refractory; NDA 207103 February 3 2015 first CDK approval ever) [5 pts]; Pfizer Groton CT + Pfizer McPherson KS + MSKCC New York NY [3 pts]; twenty-fifth mechanism class uniqueness; cyclin D1/D2/D3 regulatory subunit co-dependence absent from OEL; RB1 loss resistance mechanism absent from OEL; intermittent 3-weeks-on/1-week-off dosing schedule absent; Grade 3-4 neutropenia ~66% dose-limiting toxicity (CDK4/6 hematopoietic progenitor arrest) not mapped to OEL framework [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_palbociclib(cas: str, reading_ugm3: float) -> dict:
    """Scan palbociclib with CDK4/6 twenty-fifth-mechanism-class and PALOMA-2 context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "571190-30-2"
                "reading_ugm3": reading_ugm3,
                "context": "cdk4_6_twenty_fifth_class_first_cdk_inhibitor_pfizer_paloma2"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, cdk4_6_class_flag, twenty_fifth_mechanism_class,
    #                    first_cdk4_6_inhibitor_ever, first_pfizer_cdk_null,
    #                    g1_s_rb_checkpoint_flag, paloma2_pfs_hr_0_563,
    #                    cyclin_d_dependency_flag, h340_h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_palbociclib("571190-30-2", 0.00038))
    print(r)
    # {'hd_category': 1, 'cdk4_6_class_flag': True, 'twenty_fifth_mechanism_class': True,
    #  'first_cdk4_6_inhibitor_ever': True, 'first_pfizer_cdk_null': True,
    #  'g1_s_rb_checkpoint_flag': True, 'paloma2_pfs_hr_0_563': True,
    #  'cyclin_d_dependency_flag': True, 'h340_h350_h361_absent': True}